Mark Erlander is Chief Executive Officer of Cardiff Oncology, Inc. (CRDF). The company reported total compensation of $3,023,344 for fiscal year 2025.
| Salary | $635,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $2,266,106 |
| Non-equity incentive plan | $122,238 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $0 |
| Total | $3,023,344 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Cardiff Oncology, Inc. filed April 23, 2026, accession 0001213037-26-000006.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chief Executive Officer | $635,000 | $0 | $0 | $2,266,106 | $122,238 | $0 | $0 | $3,023,344 |
| FY2024 | Chief Executive Officer | $610,584 | $0 | $0 | $1,471,762 | $319,030 | $0 | $0 | $2,401,376 |
Totals as disclosed in each year's own compensation disclosure for Cardiff Oncology, Inc..
| Peer-group chief executive median | $8,429,887 |
|---|---|
| Difference from that median | $-5,406,543 |
| Percentile within the disclosed peer group | 1st |
| Peers with a disclosed figure | 1 |
Medians and percentiles are computed across the peer group Cardiff Oncology, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Mark Erlander this page | Chief Executive Officer | $3,023,344 |
| Roger Sidhu | Chief Medical Officer | $2,273,805 |
| James Levine | Chief Financial Officer | $1,545,615 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Cardiff Oncology, Inc. compensation brief.
Mark Erlander's compensation sits inside Cardiff Oncology, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.